Serum Amyloidogenic Nanoplaques and Cytokines in Alzheimer's Disease: Pilot Study in a Small Naturalistic Memory Clinic Cohort.
Alzheimer’s disease
Thioflavin T
amyloid
amyloid-β peptide
biomarkers
cytokines
fluorescence
serum
Journal
Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863
Informations de publication
Date de publication:
2022
2022
Historique:
pubmed:
26
2
2022
medline:
14
4
2022
entrez:
25
2
2022
Statut:
ppublish
Résumé
Neuroinflammation is a central component of Alzheimer's disease (AD) and correlates closely with amyloid pathology. Markers of inflammation such as cytokines, and amyloidogenic aggregates, so-called nanoplaques, are both promising biomarker candidates for AD. We have previously shown that there is a relationship between the levels of nanoplaques and cytokines in cerebrospinal fluid, but it is unknown whether this association extends to serum. Investigate in a naturalistic memory clinic cohort whether the associations between nanoplaques and cytokines in the cerebrospinal fluid extends to serum. We collected serum from 49 patients assessed for cognitive complaints at the Oslo University Hospital Memory Clinic (15 with clinical AD). We assessed the levels of serum nanoplaques with the novel Thioflavin-T fluorescence correlation spectroscopy (ThT-FCS) assay. Serum levels of nine cytokines (eotaxin-1, granulocyte colony-stimulating factor [G-CSF], interleukin [IL]-6, IL-7, IL-8, monocyte chemoattractant protein-1 (MCP-1), gamma induced protein 10 (IP-10), macrophage inflammatory protein [MIP]-1α, and MIP-1β) were quantified with a multiplex assay and read on a Luminex IS 200 instrument. Serum nanoplaques were not increased in clinical AD patients compared to non-AD memory clinic patients and nanoplaques were not associated with any cytokines. The cytokines IL-8 and G-CSF were increased in patients with clinical AD compared to non-AD patients. In this small pilot study, serum nanoplaques were not associated with serum cytokines. Nanoplaque levels could not be used to separate clinical AD patients from non-AD patients in this unselected memory clinic cohort.
Sections du résumé
BACKGROUND
Neuroinflammation is a central component of Alzheimer's disease (AD) and correlates closely with amyloid pathology. Markers of inflammation such as cytokines, and amyloidogenic aggregates, so-called nanoplaques, are both promising biomarker candidates for AD. We have previously shown that there is a relationship between the levels of nanoplaques and cytokines in cerebrospinal fluid, but it is unknown whether this association extends to serum.
OBJECTIVE
Investigate in a naturalistic memory clinic cohort whether the associations between nanoplaques and cytokines in the cerebrospinal fluid extends to serum.
METHODS
We collected serum from 49 patients assessed for cognitive complaints at the Oslo University Hospital Memory Clinic (15 with clinical AD). We assessed the levels of serum nanoplaques with the novel Thioflavin-T fluorescence correlation spectroscopy (ThT-FCS) assay. Serum levels of nine cytokines (eotaxin-1, granulocyte colony-stimulating factor [G-CSF], interleukin [IL]-6, IL-7, IL-8, monocyte chemoattractant protein-1 (MCP-1), gamma induced protein 10 (IP-10), macrophage inflammatory protein [MIP]-1α, and MIP-1β) were quantified with a multiplex assay and read on a Luminex IS 200 instrument.
RESULTS
Serum nanoplaques were not increased in clinical AD patients compared to non-AD memory clinic patients and nanoplaques were not associated with any cytokines. The cytokines IL-8 and G-CSF were increased in patients with clinical AD compared to non-AD patients.
CONCLUSION
In this small pilot study, serum nanoplaques were not associated with serum cytokines. Nanoplaque levels could not be used to separate clinical AD patients from non-AD patients in this unselected memory clinic cohort.
Identifiants
pubmed: 35213378
pii: JAD215504
doi: 10.3233/JAD-215504
pmc: PMC9108575
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Interleukin-6
0
Interleukin-8
0
Granulocyte Colony-Stimulating Factor
143011-72-7
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1459-1470Références
Cold Spring Harb Perspect Med. 2011 Sep;1(1):a006189
pubmed: 22229116
J Neurol Neurosurg Psychiatry. 2019 May;90(5):590-598
pubmed: 30630955
Alzheimers Dement. 2011 May;7(3):270-9
pubmed: 21514249
Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18176-81
pubmed: 19011092
Alzheimer Dis Assoc Disord. 2014 Jul-Sep;28(3):206-18
pubmed: 24632990
Brain. 2021 Dec 31;144(12):3727-3741
pubmed: 34619763
Neurobiol Aging. 2007 Apr;28(4):485-96
pubmed: 16600437
Alzheimers Dement. 2018 Dec;14(12):1640-1650
pubmed: 30120040
Alzheimer Dis Assoc Disord. 2020 Jan-Mar;34(1):47-53
pubmed: 31414991
Aging Cell. 2020 Nov;19(11):e13258
pubmed: 33155752
Ann Neurol. 2003 Apr;53(4):547-8
pubmed: 12666129
Transl Neurodegener. 2021 Jun 8;10(1):18
pubmed: 34099032
Acta Neuropathol Commun. 2019 Jul 26;7(1):120
pubmed: 31349874
Dement Geriatr Cogn Dis Extra. 2012 Jan;2(1):353-60
pubmed: 23012618
Semin Immunopathol. 2013 Sep;35(5):601-12
pubmed: 23732506
Nat Commun. 2019 Apr 4;10(1):1541
pubmed: 30948723
Int J Stroke. 2015 Jun;10(4):513-8
pubmed: 23489773
J Immunol Res. 2017;2017:4626540
pubmed: 28293644
Acta Neuropathol. 2009 Jul;118(1):103-13
pubmed: 19319544
Neurobiol Aging. 2006 Dec;27(12):1763-8
pubmed: 16307829
Tidsskr Nor Laegeforen. 2011 Nov 15;131(22):2254-7
pubmed: 22085955
Alzheimers Dement. 2014 Nov;10(6):844-52
pubmed: 24798886
J Alzheimers Dis. 2009;17(1):115-23
pubmed: 19494436
Neurol Ther. 2017 Jul;6(Suppl 1):15-24
pubmed: 28733960
Brain. 2011 Sep;134(Pt 9):2456-77
pubmed: 21810890
J Neuroinflammation. 2005 Oct 07;2:22
pubmed: 16212664
Mol Neurodegener. 2017 May 26;12(1):43
pubmed: 28549481
Eur J Neurol. 2007 Apr;14(4):e3-4
pubmed: 17388976
Neurobiol Aging. 2015 Sep;36(9):2597-606
pubmed: 26170132
Front Aging Neurosci. 2018 Aug 21;10:245
pubmed: 30186149
Neuropathol Appl Neurobiol. 2006 Apr;32(2):103-18
pubmed: 16599940
Neuro Oncol. 2005 Apr;7(2):122-33
pubmed: 15831231
Lancet Neurol. 2015 Apr;14(4):388-405
pubmed: 25792098
Biochem Biophys Res Commun. 2007 Dec 28;364(4):902-7
pubmed: 17963690
Front Aging Neurosci. 2014 Jul 29;6:171
pubmed: 25120476
Ann Transl Med. 2015 Jun;3(10):136
pubmed: 26207229
Neurobiol Aging. 2019 Apr;76:125-132
pubmed: 30711675
J Neuropathol Exp Neurol. 2013 Dec;72(12):1203-12
pubmed: 24226269
J Alzheimers Dis. 2020;77(2):831-842
pubmed: 32741818
Psychogeriatrics. 2017 Jul;17(4):224-230
pubmed: 28130814
BMC Neurol. 2016 Sep 26;16(1):185
pubmed: 27671345
Am J Clin Pathol. 2008 Apr;129(4):526-9
pubmed: 18343778
Nat Rev Neurol. 2017 Sep 29;13(10):612-623
pubmed: 28960209
J Alzheimers Dis. 2019;68(2):571-582
pubmed: 30814355
Alzheimers Dement (Amst). 2017 Jan 23;7:41-47
pubmed: 28239640
J Biol Chem. 2011 Apr 22;286(16):13827-33
pubmed: 21349839
J Biol Chem. 2016 Aug 5;291(32):16485-93
pubmed: 27325705
Alzheimers Dement. 2011 May;7(3):263-9
pubmed: 21514250
Mol Neurobiol. 2018 Jul;55(7):5689-5697
pubmed: 29039020
Cell. 2013 Apr 25;153(3):707-20
pubmed: 23622250
Front Aging Neurosci. 2021 Jan 08;12:608628
pubmed: 33488383
Transl Neurodegener. 2021 Apr 30;10(1):15
pubmed: 33941272
Am J Alzheimers Dis Other Demen. 2013 Feb;28(1):54-61
pubmed: 23242124